NCT02217410: A reported trial by Novartis Pharmaceuticals
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT02217410 |
|---|---|
| Title | A 12-month Randomized, Multiple Dose, Open-label, Study Evaluating Safety, Tolerability, Pharmacokinetics/Pharmacodynamics (PK/PD) and Efficacy of an Anti-CD40 Monoclonal Antibody, CFZ533, in Combination With Mycophenolate Mofetil (MMF) and Corticosteroids (CS), With and Without Tacrolimus (Tac), in de Novo Renal Transplant Recipients |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Feb. 5, 2015 |
| Completion date | Nov. 29, 2017 |
| Required reporting date | Nov. 29, 2018, midnight |
| Actual reporting date | Nov. 28, 2018 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |